MCL1 and triple-negative breast carcinoma: Encouraged by the findings from our earlier study [10] and presented in the current manuscript, which demonstrate, for the first time, that the combinatorial therapeutic option of fluoroquinolones with BH3 mimetic MIM1 - an apoptosis inducer with the capacity to inhibit Mcl-1 protein may constitute the potential new therapeutic option for the treatment of triple-negative breast cancer.